Abstract
Cell-free DNA (cfDNA) methylation-based diagnostics is a promising approach in oncology and hematooncology. Exercise impacts immune homeostasis and leads to a rapid and marked increase of cfDNA levels in blood. Since the origin of cfDNA during exercise remains elusive, the implications for liquid biopsy are unknown. In this study, we identified the source of cfDNA in 10 healthy untrained individuals before, immediately after, and 30 min after exercise, and in 6 patients with myeloid neoplasms or acute leukemia under resting conditions. A pyrosequencing assay was used to analyze the methylation levels of four CpGs, representing DNA from granulocytes, lymphocytes, monocytes, and non-hematopoietic cells. After exercise, cfDNA was almost exclusively released from granulocytes, with cell type specific proportions increasing significantly from 54.1% to 90.2%. Exercise did not trigger the release of cfDNA from lymphocytes or other analyzed cell types, whereas a small amount of cfDNA was released from monocytes. Compared to healthy people, patients with hematological malignancies show significantly higher cfDNA levels at rest with 48.1 (19.1; 78) vs. 8.5 (8.2; 9.5) ng/ml, data expressed as median (25th; 75th percentiles), and considerably higher levels of lymphocyte specific hypomethylated cg17587997 (P<.001). Hence, exercise-induced cfDNA elevations can compromise diagnostic accuracy.
Key Points
- cfDNA is a robust sample source for targeted bisulfite sequencing, enabling reliable mapping of the source cells.
- cfDNA methylation signatures differ between healthy people and patients with hematological malignancies.
- During intense exercise, cfDNA is almost exclusively derived from granulocytes, which can affect results of liquid biopsy.
Competing Interest Statement
W.W. is cofounder of Cygenia GmbH that can provide service for analysis of epigenetic signatures (www.cygenia.com).
Clinical Trial
The exploratory study did not aim to determine a clinical endpoint. No randomization, blinding, or control conditions were necessary and the study was not registered as a clinical trial.
Funding Statement
The study was supported by intramural funding (Stufe 1) of the Johannes Gutenberg University Mainz and by the German Ministry of Education and Research (WW: VIP+, 03VP06120).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The participants gave their informed consent to participate. All experimental procedures were approved by the Human Ethics Committee Rhineland-Palatine and conformed to the standards of the Declaration of Helsinki of the World Medical Association.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available from the corresponding author on reasonable request.
